The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study
Objectives: To evaluate the effect of ubiquinone and combined antioxidant therapy on mitochondrial function in non-proliferative diabetic retinopathy (NPDR) in a randomized, double-blind, phase IIa, placebo-controlled, clinical trial. Three groups of 20 patients were formed: Group 1, ubiquinone; Gro...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2016-07-01
|
| Series: | Redox Report |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1179/1351000215Y.0000000032 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849699871442862080 |
|---|---|
| author | Adolfo Daniel Rodríguez-Carrizalez José Alberto Castellanos-González Esaú César Martínez-Romero Guillermo Miller-Arrevillaga Luis Miguel Román-Pintos Fermín Paul Pacheco-Moisés Alejandra Guillermina Miranda-Díaz |
| author_facet | Adolfo Daniel Rodríguez-Carrizalez José Alberto Castellanos-González Esaú César Martínez-Romero Guillermo Miller-Arrevillaga Luis Miguel Román-Pintos Fermín Paul Pacheco-Moisés Alejandra Guillermina Miranda-Díaz |
| author_sort | Adolfo Daniel Rodríguez-Carrizalez |
| collection | DOAJ |
| description | Objectives: To evaluate the effect of ubiquinone and combined antioxidant therapy on mitochondrial function in non-proliferative diabetic retinopathy (NPDR) in a randomized, double-blind, phase IIa, placebo-controlled, clinical trial. Three groups of 20 patients were formed: Group 1, ubiquinone; Group 2, combined therapy; and Group 3, placebo (one daily dose for 6 months).Methods: Fluidity of the submitochondrial membrane in platelets was determined by examining intensity of fluorescence between the monomer (Im) and excimer (Ie). Hydrolytic activity of the mitochondrial F0F1-ATPase was evaluated with the spectrophotometric method.Results: Normal, baseline submitochondrial membrane fluidity, 0.24 ± 0.01 Ie/Im, was significantly diminished in the three study groups vs. normal values (P < 0.0001); placebo, 0.14 ± 0.01 Ie/Im; ubiquinone, 0.14 ± 0.01 Ie/Im; and combined therapy, 0.13 ± 0.00 Ie/Im. Afterward, it increased significantly (P < 0.0001), the ubiquinone group 0.22 ± 0.01 Ie/Im, combined therapy group, 0.19 ± 0.01 Ie/Im; with no changes the placebo group. Baseline hydrolytic activity of the F0F1-ATPase enzyme increased in the three study groups vs. normal values (184.50 ± 7.84 nmol PO4), placebo, 304.12 ± 22.83 nmol PO4 (P < 0.002); ubiquinone, 312.41 ± 25.63 nmol PO4 (P < 0.009); and combined therapy, 371.28 ± 33.50 nmol PO4 (P < 0.002). Afterward, a significant decrease the enzymatic activity: ubiquinone, 213.25 ± 14.19 nmol PO4 (P < 0.001); and combined therapy, 225.55 ± 14.48 nmol PO4 (P < 0.0001).Discussion: Mitochondrial dysfunction significantly improved in groups of NPDR patients treated with antioxidants. |
| format | Article |
| id | doaj-art-a5e1cbaaf6f3434db4ea3beb775dee96 |
| institution | DOAJ |
| issn | 1351-0002 1743-2928 |
| language | English |
| publishDate | 2016-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Redox Report |
| spelling | doaj-art-a5e1cbaaf6f3434db4ea3beb775dee962025-08-20T03:18:27ZengTaylor & Francis GroupRedox Report1351-00021743-29282016-07-0121419019510.1179/1351000215Y.0000000032The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled studyAdolfo Daniel Rodríguez-Carrizalez0José Alberto Castellanos-González1Esaú César Martínez-Romero2Guillermo Miller-Arrevillaga3Luis Miguel Román-Pintos4Fermín Paul Pacheco-Moisés5Alejandra Guillermina Miranda-Díaz6University Health Sciences Center, University of Guadalajara (Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara), Guadalajara, Jalisco, MéxicoSpecialties Hospital of the National Occidental Medical Centre, Mexican Social Security Institute (Hospital de Especialidades del Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social), Guadalajara, Jalisco, MéxicoSpecialties Hospital of the National Occidental Medical Centre, Mexican Social Security Institute (Hospital de Especialidades del Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social), Guadalajara, Jalisco, MéxicoSpecialties Hospital of the National Occidental Medical Centre, Mexican Social Security Institute (Hospital de Especialidades del Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social), Guadalajara, Jalisco, MéxicoUniversity Health Sciences Center, University of Guadalajara (Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara), Guadalajara, Jalisco, MéxicoUniversity Centre for Exact and Engineering Sciences, University of Guadalajara (Centro Universitario de Ciencias Exactas e Ingeniería, Universidad de Guadalajara), Guadalajara, Jalisco, MéxicoUniversity Health Sciences Center, University of Guadalajara (Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara), Guadalajara, Jalisco, MéxicoObjectives: To evaluate the effect of ubiquinone and combined antioxidant therapy on mitochondrial function in non-proliferative diabetic retinopathy (NPDR) in a randomized, double-blind, phase IIa, placebo-controlled, clinical trial. Three groups of 20 patients were formed: Group 1, ubiquinone; Group 2, combined therapy; and Group 3, placebo (one daily dose for 6 months).Methods: Fluidity of the submitochondrial membrane in platelets was determined by examining intensity of fluorescence between the monomer (Im) and excimer (Ie). Hydrolytic activity of the mitochondrial F0F1-ATPase was evaluated with the spectrophotometric method.Results: Normal, baseline submitochondrial membrane fluidity, 0.24 ± 0.01 Ie/Im, was significantly diminished in the three study groups vs. normal values (P < 0.0001); placebo, 0.14 ± 0.01 Ie/Im; ubiquinone, 0.14 ± 0.01 Ie/Im; and combined therapy, 0.13 ± 0.00 Ie/Im. Afterward, it increased significantly (P < 0.0001), the ubiquinone group 0.22 ± 0.01 Ie/Im, combined therapy group, 0.19 ± 0.01 Ie/Im; with no changes the placebo group. Baseline hydrolytic activity of the F0F1-ATPase enzyme increased in the three study groups vs. normal values (184.50 ± 7.84 nmol PO4), placebo, 304.12 ± 22.83 nmol PO4 (P < 0.002); ubiquinone, 312.41 ± 25.63 nmol PO4 (P < 0.009); and combined therapy, 371.28 ± 33.50 nmol PO4 (P < 0.002). Afterward, a significant decrease the enzymatic activity: ubiquinone, 213.25 ± 14.19 nmol PO4 (P < 0.001); and combined therapy, 225.55 ± 14.48 nmol PO4 (P < 0.0001).Discussion: Mitochondrial dysfunction significantly improved in groups of NPDR patients treated with antioxidants.https://www.tandfonline.com/doi/10.1179/1351000215Y.0000000032Diabetes mellitusDiabetic retinopathyAntioxidantsOxidative stressCo-enzime Q10Mitochondrial function |
| spellingShingle | Adolfo Daniel Rodríguez-Carrizalez José Alberto Castellanos-González Esaú César Martínez-Romero Guillermo Miller-Arrevillaga Luis Miguel Román-Pintos Fermín Paul Pacheco-Moisés Alejandra Guillermina Miranda-Díaz The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study Redox Report Diabetes mellitus Diabetic retinopathy Antioxidants Oxidative stress Co-enzime Q10 Mitochondrial function |
| title | The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study |
| title_full | The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study |
| title_fullStr | The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study |
| title_full_unstemmed | The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study |
| title_short | The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study |
| title_sort | antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non proliferative diabetic retinopathy a randomized double blind phase iia placebo controlled study |
| topic | Diabetes mellitus Diabetic retinopathy Antioxidants Oxidative stress Co-enzime Q10 Mitochondrial function |
| url | https://www.tandfonline.com/doi/10.1179/1351000215Y.0000000032 |
| work_keys_str_mv | AT adolfodanielrodriguezcarrizalez theantioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy AT josealbertocastellanosgonzalez theantioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy AT esaucesarmartinezromero theantioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy AT guillermomillerarrevillaga theantioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy AT luismiguelromanpintos theantioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy AT ferminpaulpachecomoises theantioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy AT alejandraguillerminamirandadiaz theantioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy AT adolfodanielrodriguezcarrizalez antioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy AT josealbertocastellanosgonzalez antioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy AT esaucesarmartinezromero antioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy AT guillermomillerarrevillaga antioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy AT luismiguelromanpintos antioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy AT ferminpaulpachecomoises antioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy AT alejandraguillerminamirandadiaz antioxidanteffectofubiquinoneandcombinedtherapyonmitochondrialfunctioninbloodcellsinnonproliferativediabeticretinopathyarandomizeddoubleblindphaseiiaplacebocontrolledstudy |